Roche Holding AG (OTC:RHHBY) reportedly turned down a potential blockbuster weight-loss pill in 2018, allowing Eli Lilly And Co (NYSE:LLY) to acquire the drug, now known as orforglipron, for just $50 million. Despite its initial valuation in the tens of millions, the drug is projected to generate up to $14 billion annually by 2032, highlighting the weight-loss market’s massive growth potential. The missed opportunity came as Roche opted not to exercise its “right of first refusal” on the drug, initially developed by Chugai Pharmaceutical, with which Roche has had a long-standing partnership. At the time, the Financial Times reported that the drug—then called Owl-833—was in ...